Regeneron to buy bankrupt DNA testing firm 23andMe for $256 million

23andMe Has Found a Buyer—Here’s What Might Happen to Your Genetic Data

Regeneron acquires bankrupt 23andMe for $256M, taking over its DNA database and services while pledging to uphold privacy standards.

Pharma Giant Buys Bankrupt DNA Collection Company, Acquiring Access To Largest Genetic Database On Earth

American biotechnology firm Regeneron Pharmaceuticals is buying 23andMe after submitting a winning bid of $256 million in a Monday bankruptcy auction

The story of 23andMe, famous for its innovative focus on DNA analysis, has taken an unexpected turn.This Monday, the company agreed to be acquired by Regeneron for $256 million, a figure that contrasts enormously with the maximum valuation of $6 billion that reached in 2021.According to the original report, this purchase arises after a bankruptcy auction in which Regeneron turned out to be the winning bidder.Regeneron takes the reinsBased on Tar…

Former Silicon Valley DNA Darling 23andMe Acquired by Regeneron Pharmaceuticals

Regeneron Pharmaceuticals has announced a plan to acquire the bankrupt genetic testing company 23andMe for $256 million, raising privacy concerns as the pharmaceutical giant will gain access to the genetic data of over 15 million customers.

Regeneron To Buy 23andMe For $256M After Bankruptcy: Here's What To Know

23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron's Gene-Based Drug R&D Efforts

Regeneron Pharmaceuticals’ $256 million offer was chosen the winner of 23andMe’s bankruptcy auction. Drug research never became a big part of the genetic testing company’s business, but it is getting a new life by joining Regeneron Genetics Center, a Regeneron subsidiary that analyzes genetic data for drug R&D.